Drug-Drug Interaction and Safety of AZD4041 Study (Part 1) and Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AZD4041 Study in Opioid Use Disorder (Part 2).

"Part 1a: Healthy participants will receive AZD4041 (Dose 1) orally on Day 1 and Day 9.~Part 1b: Healthy participants will receive AZD4041 (Dose 2) orally on Day 1 as a single dose.~Part 2: Participants with OUD will receive daily doses of AZD4041 from Days 1 to 7."

Healthy participants will receive itraconazole orally from Days 6 to 8 in Period 2 and Days 9 to 21 in Period 3.

Participants with OUD will receive buprenorphine (as standard of care treatment) on Day 4.

Participants with OUD will receive buprenorphine + naloxone (as standard of care treatment) on Days 4, 5, 6 and 7

Participants with OUD will receive hydromorphone (as a replacement opioid) on Days 1, 2 and 3.

"Part 1b: Healthy participants will receive matching placebo orally on Day 1 as a single dose.~Part 2: Participants with OUD will receive placebo daily from Days 1 to 7."